Evaluation of factors affecting the occurrence of second atypical fracture after bone union of the first atypical fracture.
Atypical femoral fracture
Bone union
Relapse
Teriparatide
Journal
Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
27
04
2020
revised:
21
09
2020
accepted:
26
09
2020
pubmed:
3
10
2020
medline:
22
6
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
Teriparatide is sometimes used in the treatment of atypical femoral fracture (AFF). Even if bone union is achieved, orthopedic physicians must consider the risk of relapse. This study aimed to investigate the factors affecting AFF recurrence, and to determine the appropriate treatment for osteoporosis after bone union. One hundred thirty-one consecutive AFFs in 113 Japanese patients were included. Eleven patients had AFF in the unaffected limb (9 patients) after the first AFF or re-fracture at the original fracture site (2 patients) after bone union of the first AFF was confirmed. We divided all patients into two groups: the second fracture group (22 AFFs in 11 patients) and non-second fracture group (109 AFFs in 102 patients). We compared clinical information between the 2 groups and investigated the factors affecting AFF recurrence using the Student t-, Welch t-, and chi-square tests. Although there was no significant difference in clinical characteristics between the 2 groups, multivariate analysis of factors associated with AFF recurrence identified short duration of treatment with teriparatide and active vitamin D The administration of teriparatide for as long as possible after occurrence first AFF and the use of active vitamin D
Identifiants
pubmed: 33007529
pii: S8756-3282(20)30451-8
doi: 10.1016/j.bone.2020.115671
pii:
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Teriparatide
10T9CSU89I
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115671Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.